Verisante Sells China Rights to Lung Cancer Diagnostic Device

Verisante Technology of Canada sold China rights for its Core ™ cancer diagnostic device, a laser Raman Spectroscopy (LRS) system, to an unnamed partner. The partner will make a $300,000 private placement in Verisante and be responsible for China registration, including a China clinical trial, if necessary. To close the deal, Verisante must raise an additional $2.5 million before the end of September. More details.... Stock Symbol: (OTCQX:VRSEF; TSX-V:VRS) Share this with colleagues: // //